Compare DBL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | GLSI |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 244.7M |
| IPO Year | 2011 | 2020 |
| Metric | DBL | GLSI |
|---|---|---|
| Price | $14.09 | $15.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 49.6K | ★ 111.4K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.95 | $7.78 |
| 52 Week High | $15.79 | $34.10 |
| Indicator | DBL | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 43.76 |
| Support Level | $13.95 | $14.63 |
| Resistance Level | $14.44 | $29.89 |
| Average True Range (ATR) | 0.11 | 1.40 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 28.00 | 15.68 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.